13
十月 23
06
十月 23
HKAPI Career Talk at HKU: Nurturing Biopharmaceutical Aspirations
The HR Committee successfully hosted a career talk at the University of Hong Kong, themed 'Why Should You Explore a Bio-Pharmaceutical Career?'.
06
十月 23
HKAPI 2023 Policy Address Recommendations Submission
We are pleased that the HKAPI has submitted the 2023 Policy Address Recommendations to the Hong Kong government.
19
七月 23
Primary Healthcare Sharing Session held successfully
HKAPI hosted a successful Primary Healthcare Sharing Session on July 18, 2023. The event was attended by over 60 representatives from HKAPI member, affiliate member, and associate member.
13
七月 23
Regulatory Intelligence Forum
The HKAPI Regulatory Working Group recently held a forum for its members to exchange views on regulatory intelligence. Around 60 members attended the event.
08
六月 23
HKAPI Annual Dinner 2023 – Innovate, Integrate & Impact
The HKAPI Annual Dinner 2023 on June 7th, held under the theme of Innovate, Integrate & Impact, was the first annual dinner event since 2019 due to the COVID-19 pandemic
22
五月 23
HKAPI Welcomes Four New Members
We are excited to share that the HKAPI has welcomed four new members to our organization over the past year. These companies are bringing new and diverse expertise to our organization and we are thrilled to have them on board.
19
五月 23
Pfizer Renewed as HKAPI Full Member
HKAPI is pleased to announce that Pfizer has renewed as full member of the Association.
17
五月 23
HKAPI joined the Panel at 3rd ASGH Project Pitching Sessions
We are delighted to announce that our Senior Executive Director, Ms. Sabrina Chan, was invited by the Hong Kong Trade Development Council (HKTDC) to participate in the 3rd Asia Summit on Global Health (ASGH) as one of the panelists for the Project Pitching Sessions.
05
四月 23
Appointment of New Board Members
HKAPI has announced the election of two new members to its Board of Directors. Mr Neo Lam, from Baxter, and Mr Jonathan Chin, from Boehringer Ingelheim, have been elected to join the Board and will serve until the end of this term (2024).
